New Immune-Boosting drug takes on Hard-to-Treat cancers

NCT ID NCT04485013

Recruiting now Disease control Sponsor: Tizona Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to about 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TTX-080 (an experimental drug that blocks HLA-G, a protein that helps tumors hide from the immune system)
What this could lead to: If this works, it could provide a new treatment option for people with advanced cancers that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not work or may have serious side effects. Only a small number of people will be tested, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung breast neoplasm cancer colorectal cancer colorectal neoplasm endometrium neoplasm gastric neoplasm Head and Neck Neoplasms kidney cancer lung neoplasm melanoma neoplasm Neoplasm Metastasis ovarian cancer prostate cancer renal cell carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AdventHealth Research Institute
COMPLETED

Orlando, Florida, 32804, United States
American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders
RECRUITING

Bethesda, Maryland, 20817, United States
Arizona Oncology Associates
COMPLETED

Tucson, Arizona, 85711, United States
Christiana Care Helen F. Graham Cancer Center
COMPLETED

Newark, Delaware, 19713, United States
Dana-Farber Cancer Institute
COMPLETED

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists
RECRUITING

Daytona Beach, Florida, 32117, United States
Florida Cancer Specialists
COMPLETED

Fleming Island, Florida, 32003, United States
Hoag Memorial Hospital
COMPLETED

Newport Beach, California, 92663, United States
Icahn School of Medicine at Mount Sinai
COMPLETED

New York, New York, 10029, United States
Illinois Cancer Specialists
COMPLETED

Arlington Heights, Illinois, 60005, United States
Indiana University
COMPLETED

Indianapolis, Indiana, 46202, United States
John Hopkins Kimmer Cancer Center
COMPLETED

Washington D.C., District of Columbia, 20016, United States
Maryland Oncology Hematology
RECRUITING

Silver Spring, Maryland, 20904, United States
Medical University of South Carolina
COMPLETED

Charleston, South Carolina, 29425, United States
NEXT Oncology
COMPLETED

San Antonio, Texas, 78229, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Nebraska Cancer Center Oncology Hematology West P.C.
RECRUITING

Omaha, Nebraska, 68130, United States
Northwest Cancer Specialists
COMPLETED

Vancouver, Washington, 98684, United States
Northwest Medical Specialties
COMPLETED

Tacoma, Washington, 98405, United States
Norton Cancer Institute
COMPLETED

Louisville, Kentucky, 40241, United States
Ocala Oncology Center
RECRUITING

Ocala, Florida, 34474, United States
Regions Hospital Cancer Care Center
RECRUITING

Saint Paul, Minnesota, 55101, United States
Rocky Mountain Cancer Centers
RECRUITING

Denver, Colorado, 80218, United States
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States
START Dallas
RECRUITING

Fort Worth, Texas, 76104, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Stony Brook University
COMPLETED

Stony Brook, New York, 11794, United States
Texas Oncology - Dallas
RECRUITING

Dallas, Texas, 75246, United States
Texas Oncology - Paris
RECRUITING

Paris, Texas, 75460, United States
The University of Texas MD Anderson Cancer Center
COMPLETED

Houston, Texas, 77030, United States
The University of Toledo
COMPLETED

Toledo, Ohio, 43606, United States
University of Cincinnati
RECRUITING

Cincinnati, Ohio, 45267, United States
University of Illinois
COMPLETED

Chicago, Illinois, 60612, United States
University of Oklahoma
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
University of Pittsburgh Medical Center
COMPLETED

Pittsburgh, Pennsylvania, 15232, United States
University of Southern California
COMPLETED

Los Angeles, California, 90033, United States
Vanderbilt - Ingram Cancer Center
COMPLETED

Nashville, Tennessee, 37232, United States
Washington University in St Louis
COMPLETED

St Louis, Missouri, 63110, United States
Yale Cancer Center
COMPLETED

New Haven, Connecticut, 06511, United States
Zangmeister Cancer Center
COMPLETED

Columbus, Ohio, 43219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.